about
Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patientsShort term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement: A Systematic Review and Meta-analysis.Cerebral embolic lesions detected with diffusion-weighted magnetic resonance imaging following carotid artery stenting: a meta-analysis of 8 studies comparing filter cerebral protection and proximal balloon occlusion.Use of statins in lower extremity artery disease: a review.Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication.New cerebral lesions at magnetic resonance imaging after carotid artery stenting versus endarterectomy: an updated meta-analysisGenetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure.Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study.Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings.Meta-analysis of mortality outcomes and mitral regurgitation evolution in 4,839 patients having transcatheter aortic valve implantation for severe aortic stenosis.Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.Moderate and severe preoperative chronic kidney disease worsen clinical outcomes after transcatheter aortic valve implantation: meta-analysis of 4992 patients.Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives.Developing drugs for use before, during and soon after percutaneous coronary intervention.Renal dysfunction and transcatheter aortic valve implantation outcomes.Antithrombotic therapy in TAVI patients: changing concepts.Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients.Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation.Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease.One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice.Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation.Early discharge after transfemoral transcatheter aortic valve implantation.A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation.Time for science to catch up with clinical practice?Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary interventionCorrection: Akap1 Deficiency Promotes Mitochondrial Aberrations and Exacerbates Cardiac Injury Following Permanent Coronary Ligation via Enhanced Mitophagy and ApoptosisPrevalence and characteristics of true and apparent treatment resistant hypertension in the Campania Salute Network.EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy.Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry.Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry.Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle.Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial.Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX.Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis.To EncourAGE Individualized Dual Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation: A New pAGE of an Intriguing Book.
P50
Q26780172-1A54C033-C96A-4C4A-A73C-58C38447C17FQ30241829-9A42E458-4E13-4826-935D-D8AB8F8C7F59Q30249767-D5397547-6039-4868-BDAD-58F5E603A6A9Q30854056-E9673A19-EE0A-4E83-B54E-AD478E476445Q34485974-339AA53F-F089-455F-9924-E9A82898C0CEQ34486136-B64D86E4-A980-4811-8361-E2D97D74C5F0Q35643622-A2BCC6EC-4BBB-47ED-9807-2E284CF6E733Q36974257-B67715C7-35D2-40BD-ADBC-AFA964729B6AQ37586414-2A77568F-AEA6-4658-A892-CD79318D9A92Q37864877-CF1B8DAD-B1E9-4796-8EF6-33E5F7C1D1C7Q38236970-899DBF6A-2AEA-4CD1-8635-E8BC55ED221BQ38249105-99A68552-6CD2-40FB-899D-A06C498C22D9Q38344419-DC6A2BC8-8AF6-4F56-B415-16F841C6A3C1Q38386268-58DBBC1B-753B-4B88-A869-BC70DBF54B0BQ38636949-268CD28D-F2F7-4FFD-AEEA-D5690B3EE3F7Q38708145-C351218D-CEB4-446F-9354-B395DE080934Q38820488-D8E2A815-37F3-4D76-A8E5-5383067ED4E8Q38962486-8EB29FC3-51C1-49EF-AED3-72FCA876127DQ39044549-D751CC29-1E75-422D-A0EF-849F801E4F84Q39093174-36AF5F7E-68C3-4586-A09E-C91FF341DD63Q39191699-48FEAB29-F9B7-4C39-8CAC-9245115C3313Q39586952-A9600FD5-4DDB-44A2-B16C-BF3EE49254CBQ39690599-AECC1DB0-26D1-4CA5-AF24-0BF8409C5D02Q39904581-76E934E3-372F-4B8A-8B39-91320DCF6A60Q40116423-DA371B05-3672-45B8-8221-0AA1D3F831A0Q40809602-05854DD5-BF00-4B25-B46A-E650DD17C9A3Q40833461-120F960E-85C6-416E-A425-AD1BC4337334Q41094165-1B489AAA-0351-499F-B0A2-982AD2F12CE9Q41767985-46D9F0A2-CE0D-468B-B64A-7FE3B886968BQ42333629-239F361D-B9B8-48AD-8053-9447B43A85A9Q42430441-5B3DC66E-E3F7-4081-BF2C-45B323A80119Q44059286-0E10D5D9-6DC4-4A94-833B-74E8DC4C9590Q45197667-FF5BF02A-20A4-4790-B77F-99A2508AB0C7Q46060844-DB6EC5BC-0E05-47DE-9DA8-EEB537C79EAEQ46093469-D6217C37-4BB8-40D4-A6FA-F325C9D2CA5CQ47159836-51B3BF5D-187C-4385-A0F9-AFA1F94107ECQ47208384-E0C50144-874B-4218-93AC-DC2D2E917B3FQ47862169-6559A6A1-D86E-44E6-BA9C-3E3422350460Q48657324-45F11C1D-68E6-4A72-9B90-E7DCEEF45C80Q49897223-C0ABE535-99FA-46C3-8A48-D91B3E2D0EED
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Gargiulo
@ast
Giuseppe Gargiulo
@en
Giuseppe Gargiulo
@es
Giuseppe Gargiulo
@nl
type
label
Giuseppe Gargiulo
@ast
Giuseppe Gargiulo
@en
Giuseppe Gargiulo
@es
Giuseppe Gargiulo
@nl
prefLabel
Giuseppe Gargiulo
@ast
Giuseppe Gargiulo
@en
Giuseppe Gargiulo
@es
Giuseppe Gargiulo
@nl
P106
P1153
56888483300
P21
P31
P496
0000-0003-4395-6742